Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1 age of 18 to 65 yr,~* 2 body mass index 18.5 to 25.0 kg/m2,~* 3 American Society of Anesthesiologists physical status I to III~* 4 scheduled for elective surgery with an expected duration of at least 60min under general anesthesia with intubation of the trachea or laryngeal mask~* 5 patients having given informed consent to the study~Exclusion Criteria:~* 1 patients who had participated in another clinical trial within 1 month~* 2 Patients with suspected difficult airway, bronchial asthma, chronic obstructive pulmonary disease~* 3 known neuromuscular disease~* 4 suspected malignant hyperthermia~* 5 hepatic or renal dysfunction~* 6 glaucoma~* 7 allergy to the medication that used in this trial~* 8 taking medicaments that might influence the effect of NMB agents~* 9 pregnant, or breastfeeding state~* 10 taking medication known to alter the effect of neuromuscular blocking agents( toremifene .etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- sugammadex 0.125 (Type: None): Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 0.25 (Type: None): Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 0.5 (Type: None): Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 1.0 (Type: None): Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 2.0 (Type: None): Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 10 (Type: None): Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 25 (Type: None): Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 40 (Type: None): Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 55 (Type: None): Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 70 (Type: None): Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
- Placebo (Type: None): Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3

Based on this trial design, predict the completion outcome and termination type (if applicable).